On November 17, 2020, MedAvail Holdings Inc. (f k a MYOS RENS Technology Inc.), consummated the previously announced business combination pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of June 30, 2020, by and among the company, MedAvail Inc. (MedAvail), and Matrix Merger Sub Inc. (Merger Sub). Pursuant to the Merger Agreement, Merger Sub merged with and into MedAvail, with MedAvail surviving as a wholly-owned subsidiary of the Company. The Business Combination was consummated on November 18, 2020. In connection with the consummation of the Business Combination, the registrant changed its name from MYOS RENS Technology Inc. to MedAvail Holdings Inc. Pursuant to the Merger Agreement, on November 17, 2020, Joseph Mannello, Robert J. Hariri, Louis Aronne, Christopher Pechock, Victor Mandel, Andrew Ponte, Eric Zaltas and Christopher Dewey resigned from the MYOS Board and any respective committees of the MYOS Board to which they served, which resignations were not the result of any disagreements with MYOS relating to MYOS's operations, policies or practices. Mr. Pechock resigned from his positions on the audit committee and compensation committee, Mr. Zaltas resigned from his position on the audit committee, Mr. Mandel resigned from his position on the audit committee and Mr. Aronne resigned from his position on the compensation committee. On November 17, 2020, the MYOS Board appointed Ed Kilroy, Gerard van Hamel Platerink, Gerald Gradwell, Helen Ciesielski, Glen Stettin, Rob Faulkner and Michael Kramer as members of the Company's board of directors, effective as of the Effective Time. Gerard van Hamel Platerink serves as the chairperson of the company Board. The Company Board was divided into three staggered classes of directors and each director was assigned to one of the three classes, effective as of the Business Combination Closing Date. At each annual meeting of the stockholders, a class of directors will be elected for a three-year term to succeed the directors of the same class whose terms are then expiring. The terms of the directors will expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the year 2021 for Class I directors, 2022 for Class II directors and 2023 for Class III directors. Ed Kilroy and Gerard van Hamel Platerink were appointed as Class I directors, Helen Ciesielski and Gerald Gradwell were appointed as Class II directors and Robert Faulkner, Michael Kramer and Glen Stettin were appointed as Class III directors. Additionally, on November 18, 2020, the Company Board established three standing committees an audit committee, a compensation committee and a nominating and corporate governance committee. Messrs. Kramer and Gradwell and Ms. Ciesielski were appointed as members of the audit committee, and Mr. Kramer serves as the chairperson of the audit committee. Messrs. Stettin and Kramer were appointed as members of the compensation committee, and Mr. Stettin serves as the chairperson of the compensation committee. Mr. Gradwell and Ms. Ciesielski were appointed as members of the nominating and corporate governance committee, and Mr. Gradwell serves as the chairperson of the nominating and corporate governance committee. On November 17, 2020, effective as of the Effective Time, the MYOS Board appointed Ed Kilroy as the Company's President, Ryan Ferguson as the company's, Treasurer and Secretary, Dave Rawlins as the Company's Chief Commercial Officer, Neil Prezioso as the company's Chief Pharmacy Officer, Will Misloski as the Company's Chief Marketing Officer and Fraser Mackay as the company's Chief Information Officer.